✦ LIBER ✦

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

✍ Scribed by Axel Le Cesne; Isabelle Ray-Coquard; Binh Nguyen Bui; Antoine Adenis; Maria Rios; François Bertucci; Florence Duffaud; Christine Chevreau; Didier Cupissol; Angela Cioffi; Jean-François Emile; Sylvie Chabaud; David Pérol; Jean-Yves Blay

Book ID: 117785476
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 293 KB
Volume: 11
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(10)70222-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of regorafenib for a

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

✍ Demetri, George D; Reichardt, Peter; Kang, Yoon-Koo; Blay, Jean-Yves; Rutkowski, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 348 KB

Efficacy and safety of sunitinib in pati

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

✍ George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackste 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 201 KB

Dovitinib versus sorafenib for third-lin

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

✍ Motzer, Robert J; Porta, Camillo; Vogelzang, Nicholas J; Sternberg, Cora N; Szcz 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 436 KB

Quality of life in patients with locally

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial

✍ Per Fransson; Jo-Åsmund Lund; Jan-Erik Damber; Olbjörn Klepp; Fredrik Wiklund; S 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 184 KB

Cost-effectiveness of 3-year vs 1-year a

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial

✍ Majer, I. M.; Gelderblom, H.; van den Hout, W. B.; Gray, E.; Verheggen, B. G. 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 336 KB

Efficacy and safety of erlotinib versus

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

✍ Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 381 KB